GT199900128A - 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas - Google Patents

1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas

Info

Publication number
GT199900128A
GT199900128A GT199900128A GT199900128A GT199900128A GT 199900128 A GT199900128 A GT 199900128A GT 199900128 A GT199900128 A GT 199900128A GT 199900128 A GT199900128 A GT 199900128A GT 199900128 A GT199900128 A GT 199900128A
Authority
GT
Guatemala
Prior art keywords
arilmetil
naftiridin
onas
aril
reivinded
Prior art date
Application number
GT199900128A
Other languages
English (en)
Inventor
Edward Fox Kleinman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900128A publication Critical patent/GT199900128A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE AL COMPUESTO REPRESENTADO POR LA ESTRUCTURA EN EL LUGAR INDICADO [(PIRIMIDONAS)], O LA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, CADA UNO DE "R1 Y R2" SE SELECCIONA, SEGUN SE ESPECIFICA EN EL DOCUMENTO ORIGINAL; TAMBIEN SE REIVINDICA CUANDO LAS ESTRUCTURAS DE R1 Y R2 PUEDEN SER ARILO O HETEROARILO. SUS COMPOSICIONES FARMACEUTICAS PARA TRATAMIENTO DE TRASTORNOS RESPIRATORIOS, ALERGICOS, REUMATOIDES, DE REGULACION DEL PESO CORPORAL.
GT199900128A 1998-08-11 1999-08-09 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas GT199900128A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9617698P 1998-08-11 1998-08-11

Publications (1)

Publication Number Publication Date
GT199900128A true GT199900128A (es) 2001-01-30

Family

ID=22256080

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900128A GT199900128A (es) 1998-08-11 1999-08-09 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas

Country Status (44)

Country Link
US (1) US6174895B1 (es)
EP (1) EP1104420B1 (es)
JP (1) JP2002522541A (es)
KR (1) KR20010072368A (es)
CN (1) CN1312810A (es)
AP (1) AP2001002068A0 (es)
AR (1) AR015557A1 (es)
AT (1) ATE229955T1 (es)
AU (1) AU4924999A (es)
BG (1) BG105321A (es)
BR (1) BR9912902A (es)
CA (1) CA2340180A1 (es)
CO (1) CO5130004A1 (es)
CZ (1) CZ2001485A3 (es)
DE (1) DE69904602T2 (es)
DK (1) DK1104420T3 (es)
DZ (1) DZ2866A1 (es)
EA (1) EA200100124A1 (es)
EE (1) EE200100085A (es)
ES (1) ES2188194T3 (es)
GE (1) GEP20033029B (es)
GT (1) GT199900128A (es)
HK (1) HK1038917A1 (es)
HN (1) HN1999000130A (es)
HR (1) HRP20010107A2 (es)
HU (1) HUP0103466A3 (es)
ID (1) ID27843A (es)
IL (1) IL140868A0 (es)
IS (1) IS5815A (es)
MA (1) MA26669A1 (es)
NO (1) NO20010684L (es)
NZ (1) NZ509297A (es)
OA (1) OA11591A (es)
PA (1) PA8480001A1 (es)
PE (1) PE20000950A1 (es)
PL (1) PL346005A1 (es)
PT (1) PT1104420E (es)
SK (1) SK1822001A3 (es)
SV (1) SV1999000120A (es)
TN (1) TNSN99155A1 (es)
TR (1) TR200100433T2 (es)
TW (1) TW542835B (es)
WO (1) WO2000009504A1 (es)
ZA (1) ZA200101040B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815951B2 (en) 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
EP1343528A2 (en) * 2000-11-02 2003-09-17 Research Foundation of City University of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
CA2478310A1 (en) 2002-03-15 2003-09-25 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors
KR100454750B1 (ko) * 2002-06-20 2004-11-03 삼성에스디아이 주식회사 유기 전계 발광 소자용 청색 발광 화합물 및 이를 사용한유기 전계 발광 소자
US20060079540A1 (en) * 2002-11-27 2006-04-13 Altana Pharma Ag Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE10349497A1 (de) * 2003-10-23 2005-05-25 Bayer Cropscience Ag N-substituierte Pyrazolylcarboxanilide
CA2552540A1 (en) * 2004-01-17 2005-07-28 Boehringer Ingelheim International Gmbh Use of substituted pteridines for the treatment of diseases of the respiratory tract
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1915155A1 (en) * 2005-08-03 2008-04-30 Boehringer Ingelheim International GmbH Dihydropteridinones in the treatment of respiratory diseases
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
CA2695406A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
PT2882714T (pt) * 2012-08-08 2020-02-19 Merck Patent Gmbh Derivados de (aza)isoquinolinona
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU165405B (es) * 1972-06-29 1974-08-28
US3856800A (en) * 1973-02-26 1974-12-24 Sterling Drug Inc Process of preparing 1,4-dihydro-4-oxo-7-q-3-unsubstituted-1,8-naphthyridines from cyclic alkylidenyl n-(6-q-2-pyridyl) aminomethylenemalonates
US3882132A (en) * 1973-03-08 1975-05-06 Sterling Drug Inc Preparation of 1-alkyl-1,4-dihydro-7-substituted-4-oxo-1,8-naphthyridine-3-carboxylic acids via the 3-aminomethyl analogs
CN1043993C (zh) * 1994-08-29 1999-07-07 山之内制药株式会社 萘啶衍生物及其医药组合物
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤

Also Published As

Publication number Publication date
CO5130004A1 (es) 2002-02-27
HN1999000130A (es) 2000-11-22
DZ2866A1 (fr) 2003-12-01
DE69904602T2 (de) 2003-04-30
PL346005A1 (en) 2002-01-14
GEP20033029B (en) 2003-07-25
KR20010072368A (ko) 2001-07-31
IL140868A0 (en) 2002-02-10
HUP0103466A3 (en) 2002-11-28
OA11591A (en) 2004-07-30
HRP20010107A2 (en) 2002-02-28
PA8480001A1 (es) 2000-09-29
BG105321A (en) 2001-12-29
NO20010684L (no) 2001-04-09
ATE229955T1 (de) 2003-01-15
PE20000950A1 (es) 2000-09-27
MA26669A1 (fr) 2004-12-20
CZ2001485A3 (cs) 2002-05-15
EP1104420B1 (en) 2002-12-18
BR9912902A (pt) 2001-05-08
CN1312810A (zh) 2001-09-12
TW542835B (en) 2003-07-21
DK1104420T3 (da) 2003-01-13
CA2340180A1 (en) 2000-02-24
SV1999000120A (es) 2000-09-05
AP2001002068A0 (en) 2001-03-31
TNSN99155A1 (fr) 2005-11-10
AR015557A1 (es) 2001-05-02
DE69904602D1 (en) 2003-01-30
ES2188194T3 (es) 2003-06-16
EP1104420A1 (en) 2001-06-06
EA200100124A1 (ru) 2001-10-22
HUP0103466A2 (hu) 2002-02-28
SK1822001A3 (en) 2002-08-06
NO20010684D0 (no) 2001-02-09
ID27843A (id) 2001-04-26
HK1038917A1 (zh) 2002-04-04
EE200100085A (et) 2002-08-15
ZA200101040B (en) 2003-01-07
US6174895B1 (en) 2001-01-16
NZ509297A (en) 2003-11-28
AU4924999A (en) 2000-03-06
IS5815A (is) 2001-01-16
WO2000009504A1 (en) 2000-02-24
JP2002522541A (ja) 2002-07-23
PT1104420E (pt) 2003-03-31
TR200100433T2 (tr) 2001-07-23

Similar Documents

Publication Publication Date Title
GT199900128A (es) 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas
DOP2002000429A (es) Imidazotriazinas
MX9203050A (es) Compuestos de analogos de triptamina.
MD809C2 (ro) (-)-Enantiomer cis-4-amino-1-(2-hidroximetil -1,3-oxatiolan-5-il)-(1H)-pirimidin-2-on sau sarea lui, sau esterul lui, sau sarea esterului lui, amestec de (-)-enantiomer şi (Ş)-enantiomer, procedeu de obţinere a lor, compoziţie antivirotică şi procedeu de tratament al mamiferelor, inclusiv al omului, ce suferă de infecţii virotice sau sunt susceptibile faţă de aceste infecţii
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
TW366347B (en) Antiviral pharmaceutical compositions comprising 1,3-oxathiolane nucleoside analogues
ATE438646T1 (de) Substituierte pyrrolochinoline und pyridochinoline als serotonin- agonisten und- antagonisten
NO20013143D0 (no) Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med enökning av AT-1 eller AT-2 reseptorer
DK1353911T3 (da) Antivirale midler
GR3036655T3 (en) Use of IL-4 receptors for the therapy, prophylaxis and diagnosis of allergic, viral, paracitic and bacterial diseases, as well as of fungal infections.
HK1077518A1 (en) Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
HUP9801571A2 (hu) Zidovudin, 1592U89 és 3TC vagy FTC szinergetikus kombinációi
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
BR9812718A (pt) Uso de pelo menos 0,5%, em peso, de água como um aditivo em uma composição de vaporizador para cabelo, e, composição de vaporizador para cabelo
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
GEP20074132B (en) Use of adenosine receptor a1 antagonists for treatment of pulmonary disease
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
BR9712466A (pt) Aplicação de adamantanaminas ou compostos de estrutura análogo para combater o vìrus da doença de borna e para a profilaxia e tratamento de doenças emocionais e outras perturbaçoes ligadas com infecçoes do vìrus bd homem e animal
AR009523A1 (es) Derivado de pirimidina 2,4-disustituida, procedimiento para preparar el mismo y una composicion farmaceutica que lo contiene.
ES2083708T3 (es) Nuevas piperazinilalcoil-3 dihidro-2,3,4h-benzoxazina-1,3 onas-4 sustituidas, su preparacion y su aplicacion en terapeutica.
BR9815335A (pt) Uso de antagonistas de receptor de endotelina.
ATE318819T1 (de) Pyrazinochinoxalin-derivate als serotonin- agonisten und -antagonisten
BR0011845A (pt) Complexo farmacêutico
BR9909471A (pt) Formas vi e cristalina de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento ou profilaxia de uma infecção viral em ser humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol
DE60321554D1 (de) Neue analoga von nitrobenzylthioinosin